We have
developed 55
new or improved
tests to support
the diagnosis
of allergic and
autoinmune
diseases in the
last 5 years
Extensive service
offering, delivering
the support you need
Efficient
Fully automated, scalable, Phadia
Laboratory Systems with track integration
possible
• Phadia TM Prime & Phadia TM
LabCommunity™ software supporting lean
working and system maintenance
•
Reliable
Outstanding supplier standards
(quality and delivery)
• Dedicated R&D and manufacturing
facilities certified to ISO 13485:2016
•
1 Crameri R. Allergy 2013;68: 693-694.
2 Park KHP, et al. Ann Lab Med 2018;38:23-31.
3 Thermo Fisher Scientific. Data on File.
4 Werkstetter KJ, et al. Gastroenterology 2017; doi:
10.1053/j.gastro.2017.06.002.
5 Wulandari AA, Schulz J, Hartmann F, Dignass A,
Stein J. Poster No 119 presented at 11th Congress of
ECCO, Amsterdam, Netherlands, 2016 e 48.
6 Matthson Alm L, et al. Clin Exp Rheumatol
2017;36(1):144-152.
7 Alpini C, et al. (2010). “Role of a new FEIA assay in
systemic connective tissue disease diagnosis.” EliA
Journal(Special Edition 1): 3.
8 Baptista-Fernandes I, et al. (2010). “Performance of
a new screening test for connective tissue disease
specific antibodies compared to HEp2 screening.”
EliA Journal(Special Edition 1): 4.
9 Bonroy C, et al. (2013). “Automated indirect
immunofluorescence antinuclear antibody analysis
is a standardized alternative for visual microscope
interpretation.” Clinical Chemistry and Laboratory
Medicine 51(9): 1771-1779.
10 Elhage, et al. (2013). “ANA SCREENING WITH
THE ELIA CTD KIT IN PATIENTS WITH SYSTEMIC
SCLEROSIS.” Controversies in Rheumatology &
Autoimmunity (CORA).
11 Jeong S, et al. PLoS ONE 2017;12(3).
12 Korsholm T, et al. Scandinavian Journal of
Rheumatology 2014; 43: 89.
13 Martínez, MJ, et al. (2010). “A comparison
between two enzyme-linked immunosorbent
assays and an indirect immunofluorescence
test for Antinuclear Antibodies screening.” EliA
Journal(Special Edition 1): 5.
14 Morozzi G, et al. (2012). “A new strategy to detect
ANA: IIF HEp-2 cells at second level after the EliA
CTD Screen test. Is the algorithm correct?” Immuno
Diagnostics Journal 2: 3-4.
15 Op De Beeck K, et al. Autoimmunity Reviews
2011;10(12): 801-808.
16 Otten HG, et al Clin Exp Rheumatol 2017;35:
462-470.
17 Ougnou M, et al. Clinical Chemistry and
Laboratory Medicine 2017;49:S215.
18 Pereira LM, et al. (2010). “Evaluation of a novel
automated CTD Screen for Connective Tissue
Diseases.” EliA Journal (Special Edition 1): 6-7.
19 Robier C, et al. Clinical Chemistry and Laboratory
Medicine 2016;54(8):1365-1370.
20 Sánchez-Castañón M, et al. (2010). “Evaluation
of CTD Screen on the ImmunoCAP 100 System:
Confirmed Diagnosis Samples and Consecutive
Unknown Routine Samples.” EliA Journal (Special
Edition 1): 8-9.
21 van der Pol P, et al. Clin Chim Acta 2018;476:
154-159.
22 Viander M, et al. (2011). “Clinical evaluation
of EliA CTD Screen in CTD patients and
control samples in comparison to ANA
immunofluorescence (IIF) on HEp-2 cells.” 10th
Dresden Symposium on Autoantibodies, Dresden,
September 2011.
23 Watanabe N, et al. The Japanese journal of clinical
pathology 2014; 62(4): 315-323.
24 Willems P, et al. Clin Chem Lab Med 2018; 24:
909-918.
*The ImmunoCAP product portfolio included
+550 whole allergens, +100 allergen components,
ImmunoCAP™ Phadiatop allergen screen,
unique markers such as tryptase and ECP, the
ImmunoCAP ™ Rapid point of care test, and the
ImmunoCAP ISAC allergen microarray (validated in
>250 studies3)
Holistic
Autoimmunity Application Laboratory for
support with discrepant results
• Comprehensive clinical and laboratory
training offerings
•
9
HHE 2019 | hospitalhealthcare.com
**EliA gastrointestinal tests include: EliA Celikey,
EliA™ GliadinDP, EliA™ Calprotectin 2, EliA™ ASCA,
EliA™ Parietal Cell, and EliA™ Instrinsic Factor
†EliA rheumatic disease tests include: EliA CCP,
EliA™ Rheumatoid Factor Isotypes, EliA CTD Screen,
EliA™ SymphonyS, EliA™ CTD parameters,
EliA™ PR3S, EliA™ MPOS, EliATM GBM, EliA™
Cardiolipin and EliA™ β2-glycoprotein